Climb Bio reports Phase 1 CLYM116 data with durable suppression
Climb Bio announced Phase 1 data for CLYM116 showing a ~29-day half-life and rapid, durable APRIL and IgA suppression with favorable tolerability.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.